Proteros Appoints Dr. Torsten Hoffmann as Chief Scientific Officer
News Jun 30, 2015
Proteros biostructures GmbH has announced the appointment of Dr. Torsten Hoffmann as Chief Scientific Officer (CSO), effective from July 1st, 2015. In this newly created role at Proteros, he will support the further growth of the Proteros Discovery business and act as Member of the Management Board.
Dr. Hoffmann has more than 18 years of international scientific and research management experience. Before joining Proteros, Dr. Hoffmann was Chief Scientific Officer at Denmark-based Zealand Pharma A/S and Head of Discovery Chemistry at Roche in Basel.
He is inventor of an anti-emetic medicine which received FDA approval as Akynzeo® in 2014. Under his leadership at Roche more than 20 new chemical entities entered into clinical trials and 52 new chemical lead series were created.
From 2005 to 2013, Dr. Hoffmann assumed increasing responsibility at Roche, including Head of Discovery Chemistry with responsibility for 170 employees at the company's headquarters in Basel, Switzerland. At Zealand Pharma he was responsible for all R&D activities of the company and establishing a broad R&D pipeline.
The work under leadership of Dr. Hoffmann is documented in over 280 peer reviewed publications and 540 patent applications. He holds a Ph.D. in Chemistry from the Eidgenössische Technische Hochschule (ETH) in Zurich, Switzerland with Prof. Dieter Seebach, and did postdoctoral research with Prof. Richard Lerner at The Scripps Research Institute in La Jolla, CA, US.
"I am delighted to welcome Dr. Torsten Hoffmann to the team of Proteros. His track record in drug discovery and outstanding management expertise in both pharma and biotech companies will support us in achieving our further growth plans over the coming years," commented Dr. Torsten Neuefeind, CEO of Proteros. "Along with this and complementary to Dr. Peter Reinemer's function as COO, Dr. Hoffmann will be a great addition to our team."
Dr. Torsten Hoffmann added: "I am very impressed by the capabilities and the attractive business model of Proteros. The unique expertise in working on the most challenging targets and a prosperous business, working with almost all the big pharma companies, gives Proteros an outstanding position. It will be a pleasure to work with this highly motivated team."
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
BOC Sciences Continues to Enlarge Its Publication Collection Using BOC Sciences ProductsNews
BOC Sciences continues to add more publication items that used BOC Sciences products in their researches to its already existing collection.READ MORE